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                                       ABBREVATIONS 
DM    -      Diabetes Mellitus  
FBS   -  Fasting Blood Sugar  
GDM  -  Gestational Diabetes Mellitus  
HbAIc  -  Glycosylated Haemoglobin  
HTN   -  Hypertension  
IFG    -  Impaired Fasting Glucose  
IGT    -  Impaired Glucose Tolerance  
NIDDM  -  Insulin Dependent Diabetes Mellitus  
OGTT  -  Oral Glucose Tolerance Test  
UKPDS  -  United Kingdom Prospective Diabetes Study  
IHD    -  Ischemic Heart Disease  
NPDR  -  Nonproliferative Diabetic Retinopathy  
PDR    -  Proliferative Diabetic Retinopathy  
AOD   -  Age of onset of diabetes  
LDL    -  Low Density Lipoprotein  
HDL   -  High Density Lipoprotein  
TGL    -  Triglyceride  
Mg    -  Magnesium  
CPG    -  Capillary Blood Glucose   
ADA   - American Diabeties Association
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INTRODUCTION 
Diabetes mellitus is a metabolic disease characterised by 
hyperglycemia; results from defects from insulin secretion, insulin action 
or both. The chronic hyperglycemia of diabetes is associated with long 
term damage, dysfunction and failure of various organs like kidneys, 
eyes, nerves ,blood vessels and heart. 
Diabetes mellitus is classified on the basis of pathogenic process 
that leads to hyperglycemia. There are two broad categories of diabetes 
mellitus, designated as Type1 and Type 2.Depending on the etiology of  
the diabetes, factors contributing to hyperglycemia include reduced 
insulin secretion, increased glucose production, decreased glucose 
utilization. The metabolic dysregulation associated with diabetes cause 
pathophysiological changes in multiple organ systems. Long term 
complications of diabetes include retinopathy, nephropathy, peripheral 
neuropathy and foot ulcers. Patients with diabetes have increased risk of 
atherosclerosis and cardiovascular diseases. Hypertension and 
dyslipidemia are commonly associated with diabetes mellitus. 
Diabetes mellitus is characterized by abnormalities of 
carbohydrate, protein and fat metabolism. The basis of these 
abnormalities is the deficient action of insulin on target tissues. Defective 
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tissue action results from inadequate insulin secretion and/or defective 
tissue response to insulin. Insulin is an anabolic hormone and several 
minerals act as cofactors in the enzyme reaction s regulated by insulin. 
Deficiency of certain minerals such as potassium, magnesium, zinc, 
chromium and vitamins such as vitamin E may worsen the carbohydrate 
intolerance. 
Magnesium is one of the major intracellular cations. Intracellular 
magnesium is an important cofactor for various enzymes, transporters and 
nucleic acids that are essential for normal cellular function ,replication 
and energy metabolism. Total body magnesium is about 25 grams of 
which fifty percent resides in bone ,whereas almost all of the extraskeletal 
magnesium is located intracellularly. Normal concentration of serum 
magnesium and serum calcium is imperative for normal neuromuscular 
activity. Magnesium plays an essential role in carbohydrate metabolism 
and insulin action. Magnesium acts as a cofactor in glucose transport 
mechanism of cell membranes and various intracellular enzymes involved 
in carbohydrate metabolism. The concentration of serum magnesium is 
relatively constant whereas a considerable proportion of people with 
diabetes have reduced serum magnesium concentration. 
Magnesium deficiency is associated with hypocalcemia, 
hypokalemia and arrhythmias and hence correlates with a higher 
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mortality /morbidity in critical care patients. Magnesium deficiency has a 
negative impact on glucose homeostasis and insulin sensitivity in patients 
with diabetes and hence in the development of complications such as 
nephropathy, neuropathy, retinopathy. Low serum magnesium is a strong 
independent predictor for development of diabetes. The present study was 
chosen to unwind the association of low serum magnesium concentration 
with micro and macro vascular complications of diabetes, in both type1 
and in type 2.  
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AIMS AND OBJECTIVES 
1. To estimate the fasting serum magnesium concentration in 
patients with diabetes mellitus. 
2. To correlate the serum magnesium concentration with  micro 
and macro vascular complications of diabetes mellitus such as 
retinopathy, neuropathy, nephropathy, hypertension and  ischaemic heart 
disease. 
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DIABETES MELLITUS 
Diabetes mellitus (DM) is a metabolic disorder characterized by 
chronic hyperglycaemia due to defects in insulin secretion and/or insulin 
action.. Few of the mechanisms behind the production of hyperglycemia 
include decreased level of insulin secretion, reduced level of glucose 
utilization, and increased endogenous production of glucose2  
Diagnosis: 
DM is a biochemical diagnosis based on fasting and postprandial 
(2h) glucose levels during a 75g OGTT. In 1997, the American Diabetes 
Association (ADA)1 proposed lowering the normal fasting plasma 
glucose level to <6.1mmol/L and the threshold for diabetes to 
≥7.0mmol/L. They also recommended that fasting plasma glucose was 
the preferred diagnostic test (outside of pregnancy) in order to reduce the 
number of OGTT needed.  In 2010, the ADA and WHO introduced 
HbA1c > 6.5% as a diagnostic criterion for DM1. A diagnosis of diabetes 
is confirmed in any person with typical hyperglycaemic symptoms (e.g. 
polyuria, polydipsia, weight loss), with a random or postprandial blood 
glucose ≥11.1mmol/L or fasting plasma glucose ≥7mmol/L. In 
asymptomatic patients or those with intercurrent illness, a second 
abnormal result is necessary to establish a definitive diagnosis. 
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Classification 
 Diabetes was classified as insulin-dependent DM (IDDM) or type 
1 diabetes, and non-insulin-dependent DM (NIDDM) or type 2diabetes. 
In 1997, the updated classification of diabetes retained the terms type 1 
and  type  2  diabetes,  discarding  the  terms  IDDM  and  NIDDM.  The  
updated classification system focused on the specific underlying 
aetiology of diabetes. 
Aetiological classification of diabetes mellitus: 
1.  Type 1 diabetes (5–10% of cases)1,2: B-cell destruction. 
 • Includes autoimmune and idiopathic forms. 
2.  Type 2 diabetes (90% of cases)1,2: defective insulin secretion, 
usually with defective insulin action. 
3.  Other specific types: 
• Genetic defects of B-cell function: 
• Maturity onset diabetes of the young (MODY). 
• Mitochondrial DNA mutations. 
• Neonatal diabetes. 
• Genetic defects of insulin action: 
• Lipodystrophies. 
• Insulin receptor mutations (includes type A insulin resistance, 
leprechaunism, Rabson–Mendenhall syndrome). 
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• Rare downstream insulin-signalling defects. 
• Monogenic obesity/hyperphagia (e.g. leptin deficiency). 
• Diseases of the exocrine pancreas: 
• Pancreatitis, trauma, pancreatectomy, neoplasia, pancreatic destruction 
(including cystic fibrosis and haemochromatosis), others. 
• Endocrinopathies: 
• Cushing’s syndrome, acromegaly, phaeochromocytoma, glucagonoma, 
hyperthyroidism, autoimmune polyglandular syndrome 1 and 2, others. 
• Drug- or chemical-induced: 
• Glucocorticoids, thyroid hormone, diazoxide, B-adrenergic agonists, 
thiazides, G-interferon, antiretroviral treatment (HIV). 
• Infections: 
• Congenital rubella, cytomegalovirus (CMV), others. 
• Uncommon forms of immune-mediated diabetes: 
• ‘Stiff man’ syndrome (type 1 diabetes, rigidity of muscles, painful 
spasms), anti-insulin receptor antibodies, others. 
• Other genetic syndromes associated with diabetes: 
• Down’s syndrome, Klinefelter’s syndrome, Turner’s syndrome, 
Wolfram syndrome (or DIDMOAD—diabetes insipidus, DM, optic 
atrophy, and sensorineural deafness), Friedreich’s ataxia, Huntington’s 
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chorea, Lawrence–Moon–Biedl syndrome, myotonic dystrophy, Prader–
Willi syndrome, others. 
4. Gestational diabetes mellitus. 
The vast majority of patients with diabetes have either type 1 
diabetes (secondary to autoimmune-mediated B-cell destruction and 
absolute insulin deficiency) or type 2 diabetes (due to insulin resistance 
and defects of insulin secretion). Although the remaining aetiological 
subtypes  account  for  <10%  of  all  diabetes  cases,  it  is  important  to  
consider these rarer causes of diabetes, which comprise the entire 
differential diagnosis, in order to facilitate personalized management of 
these patients. Rarer forms, such as maturity onset diabetes of the young 
(MODY), largely arise in young adults. These individuals are often 
assumed to have type 1 or type 2 diabetes and frequently experience long  
delays before the correct diagnosis is reached. 
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 TYPE 1DIABETES TYPE 2 DIABETES 
Peak age of onset 12 60 
Etiology Autoimmune beta cell 
destruction 
Insulin resistance, beta 
cell dysfunction 
Beta cell Antibody Ø 90% No 
Insulin dependent Yes No 
DKA Yes No 
Obesity Uncommon Common 
Treatment Insulin Diet, OHA+/- Insulin 
 
Assessment of the newly diagnosed patient 
There are two issues to address in a patient with a new diagnosis of 
diabetes: firstly, what the immediate management (inpatient vs outpatient, 
optimal treatment) is and, secondly, what the underlying aetiology is. 
Assigning aetiology is usually most challenging in those diagnosed in the 
second to fourth decades of life where there is overlap of clinical features 
between the common and rarer forms of diabetes. Reassessment over the 
first  year  or  so  after  diagnosis  can  be  helpful.  If  in  any  doubt  over  
whether this is type 1 diabetes, be safe and commence insulin. 
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• History: acute or insidious onset, family history of diabetes, presence of 
other autoimmune diseases, ethnic origin. 
• Examination: BMI, acanthosis nigricans, vitiligo. Evaluation of 
precipitating cause or infection. 
• Investigations: HbA1c; renal, liver, and thyroid function; lipid profile. 
Ketones (urine or blood) and venous bicarbonate to assess for DKA. 
Test for B-cell antibodies in younger patients (<45 years at diagnosis). 
Causes of diagnostic confusion 
• Latent autoimmune diabetes of adulthood (LADA). This presents like 
type 2 diabetes but is a form of type 1 diabetes with insidious onset, 
defined by the presence of any B-cell antibody. Treated like type 2 
diabetes, but progression to insulin is usually more rapid. 
• Ketosis-prone diabetes (KPD). This presents with DKA or ketosis, but 
insulin requirements decline over weeks / months, and insulin can often 
be stopped. Most commonly seen in patients of African origin who are 
antibody negative. These patients are prone to develop  ketosis again 
during illness . 
• Monogenic diabetes. 
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Genetics 
Type 1 diabetes 
The overall lifetime risk of developing type 1 diabetes  is currently 0.4%1. 
This risk increases to: 
• 1–2% if your mother has type 1 diabetes. 
• 3–6% if your father has type 1 diabetes. 
• 5–6% if a sibling has type 1 diabetes. 
• Monozygotic twins have 750% concordance rate by age 40 years. 
Early linkage studies identified the importance of the human 
leukocyte antigen (HLA) genes of the major histocompatibility complex 
(MHC) in type 1 diabetes susceptibility. These variants account for half 
of the heritability of type 1 diabetes. The HLA class II DR and DQ loci 
(respectively encoded by genes DRB and DQB) account for almost all 
type 1 diabetes susceptibility from this region. >90% of patients with type 
1 diabetes carry at least one copy of the DRB*301-DQB*201 or 
DRB*401-DQA*301-DQB*302 (allele numbers after asterisk). 
Other susceptibility loci include variants in the gene encoding 
insulin (INS) which confers a 2-fold increased risk. More recent genome-
wide association studies (GWAS) have increased the total number of loci 
associated with type 1 diabetes to >40; however, these loci have much 
lower effect size than the HLA or INS genes. 
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These genetic studies have confirmed that the pathogenesis of type 
1 diabetes involves disordered immune regulation. Indeed, i levels of islet 
cell antibodies (ICA), anti-glutamic acid decarboxylase (GAD) 
antibodies, and anti-tyrosine phosphatase antibodies (anti-IA-2 
antibodies) are usually detected at diagnosis. The presence of all three 
antibodies give a non-diabetic individual an 88% chance of developing 
type 1 diabetes over the next 10 years. 
Type 2 diabetes 
The importance of genetic background in the aetiology of type 2 
diabetes is well established from family and twin studies (concordance 
between monozygotic twins is 60–100%)2. Heritability of type 2 diabetes 
is estimated at 72%. 
• So far, >70 genetic susceptibility variants for type 2 diabetes have been 
detected, largely through GWAS. 
• TCF7L2 (encoding transcription factor 7-like 2 protein) in chromosome 
10q is the susceptibility locus, with the largest effect on type 2 diabetes 
risk, described to date, with a per-allele odds ratio of 71.4. 
• Together, the genetic loci found so far only explain a small proportion 
(710%) of the overall heritable risk for type 2 diabetes. 
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• Ongoing research is focused on identifying rare genetic variants which 
might account for the missing heritability in type 2 diabetes. 
• Potential areas of clinical translation include risk prediction, prevention, 
pharmacogenetics, and development of novel therapeutics. 
Maturity onset diabetes of the young (MODY) 
MODY, the commonest cause of monogenic B-cell dysfunction, is 
estimated to be the underlying cause in 0.5–1% of all patients with 
diabetes1. 
A typical ‘MODY patient’ has young age of onset (<45 years, 
frequently <25 years), autosomal dominant family history of diabetes, 
absence of autoimmune markers, absence of insulin resistance and 
remains C-peptide positive, even if insulin-treated. Mutations in ten 
different genes have been associated with the MODY phenotype; 
however, in clinical practice, the vast majority of MODY cases are due to 
heterozygous mutations in genes encoding the enzyme glucokinase 
(GCK) and the nuclear transcription factors hepatocyte nuclear factor 1A 
(HNF1A), hepatocyte nuclear factor 4A (HNF4A), and hepatocyte 
nuclear factor 1B (HNF1B). HNF1A-MODY (previous name MODY3) 
• Accounts for 30–70% of MODY cases. 
• Associated with a progressive defect of insulin secretion which can be 
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complicated by severe hyperglycaemia (1/3 patients eventually require 
insulin therapy) and frequent microvascular complications. 
• Low renal threshold for glucose. 
• Importantly, these patients are exquisitely sensitive to sulfonylureas. 
Low doses (e.g. gliclazide 40mg od) are recommended as first-line 
pharmacological therapy, often maintaining excellent glycaemic control 
for years. Insulin can be stopped in those who were assumed to have type 
1 diabetes at onset of diabetes. 
• Low C-reactive protein (<0.5mg/L). 
HNF4A-MODY (previous name MODY1) 
• Accounts for 5–10% of MODY cases. 
• Clinical presentation similar to HNF1A-MODY (except normal renal 
glucose threshold). 
• Also sensitive to sulfonylureas (b see HNF1A-MODY above). 
• Neonatal hyperinsulinaemia and hypoglycaemia associated with  
acrosomia in affected neonates. 
GCK-MODY (previous name MODY2) 
• Accounts for 30–70% of MODY cases. 
• Results in a raised threshold for glucose-stimulated insulin secretion, 
but importantly insulin secretion remains regulated. 
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• Lifelong, mild, stable fasting hyperglycaemia (fasting plasma glucose 
5.5–8mmol/L and HbA1c <8%). Low increment of glucose rise following 
a carbohydrate challenge. 
•  GCK-MODY  can  be  diagnosed  at  any  age.  Patients  are  often  
asymptomatic, with hyperglycaemia found during screening. 
• Diabetes-related microvascular complications are not observed. 
• Patients should be managed on diet alone (insulin is usually only 
required during pregnancy if the fetus is macrosomic). 
• Secondary care follow-up is not usually required. 
HNF1B-MODY (previous name MODY5) 
• Also known as renal cysts and diabetes (RCAD) syndrome. 
• Accounts for 5–10% of cases of MODY. 
• Clinical features include malformations of the genitourinary system 
(commonly renal cysts and other renal developmental abnormalities), 
pancreatic atrophy, and exocrine insufficiency. 
• Not sensitive to sulfonylureas. 
Management of MODY in pregnancy 
Although MODY is an uncommon cause of GDM, women with MODY 
often present with dysglycaemia in pregnancy. Most will be managed 
according to routine guidelines. 
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For those with HNF1A/HNF4A-MODY already well controlled on 
low-dose SU agents prior to pregnancy, there is a good argument for 
using glibenclamide pre-conception (safe in type 2 diabetes) and 
continuing as long as good control is maintained. 
In HNF4A-MODY, an affected fetus can develop 
hyperinsulinaemia, macrosomia, and neonatal hypoglycaemia. Seek 
specialist advice on fetal monitoring. 
In GCK-MODY, treatment (with insulin) is only recommended if 
macrosomia is developing. Seek specialist advice. 
Neonatal diabetes1 
• Affects 71 in 100,000–150,000 live births. 
• Diabetes diagnosed before 6 months is likely to be one of the 
monogenic subtypes of neonatal diabetes, rather than type 1 diabetes.  
• Transient neonatal diabetes (TNDM): diabetes usually remits within  
3 months—chromosome 6q24 imprinting abnormalities (70% cases), 
mutations in the KATP channel genes (20% cases). 
• Permanent neonatal diabetes (PNDM): mutations in KCNJ11 and 
ABCC8 genes, respectively encoding the Kir6.2 and SUR1 subunits of the 
KATP channel (50% cases); insulin gene mutations (10–15% cases). 
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• Patients with KCNJ11 and ABCC8 mutations can be effectively treated 
with high-dose sulfonylureas and insulin stopped. 
• 72% cases with KATP channel gene mutations have additional 
neurological features (DEND syndrome—developmental delay, epilepsy, 
and neonatal diabetes). 
• INS mutations should be treated with insulin sensitizers or insulin. 
Mitochondrial diabetes1 
• Due to mutations in mitochondrial DNA (most common is an A-to-G 
point mutation at position 3243 in the tRNA leucine gene). 
• Maternal inheritance. 
• Commonly associated with sensorineural deafness (MIDD: maternally 
inherited diabetes and deafness). 
• Clinical features include CNS disease, ophthalmic disease (e.g. macular 
retinal dystrophy), myopathy, cardiac disease (e.g. LVH), and renal 
disease. 
• Clinical phenotype can be variable, even within the same family, due to 
heteroplasmy. 
Genetic causes of severe insulin resistance 
• Characterized by young onset of severe insulin resistance, e.g. 
acanthosis nigricans, dyslipidaemia, hypertension, hepatic steatosis, 
PCOS. This constellation of features, particularly in non-obese patients, 
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should raise suspicion of a genetic cause. Treatment can be challenging. 
Exercise and insulin sensitizers are first line, then high-dose insulin 
(concentrated U-500 insulin may be helpful). 
• Lipodystrophies. Insulin resistance plus abnormal fat distribution, e.g. 
loss of fat from limbs and increased central and ectopic fat. The classic 
Dunnigan familial partial lipodystrophy is caused by mutations in LMNA. 
Mutations in PPARG present with a similar phenotype. The 
lipodystrophies are more readily diagnosed in female patients. 
• Insulin receptor mutations. Present  with  a  range  of  severities  but,  in  
addition to severe insulin resistance, can present initially with fasting 
hypoglycaemia and growth defects and hyperandrogenism in women. 
Diagnostic genetic testing 
Diagnostic testing is available for the MODY subtypes, neonatal 
diabetes, mitochondrial mutations (particularly, the common A3243G 
variant), and the lipodystrophies (LMNA/PPARG).  
Diabetic eye disease1 
Diabetic retinopathy (DR) is a complication of diabetes, resulting 
from damage to the small blood vessels, generally occurring 10 years 
after  diabetes  onset  (which  may  be  some  years  before  the  diagnosis  of  
type 2 diabetes). DR is the leading cause of blindness in the working age 
population. Cataracts are also more common in people with diabetes. DR 
is extremely common with long durations of diabetes48. 
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Classification and features of diabetic retinopathy 
• Background retinopathy  
• Microaneurysms. 
• Haemorrhages—dot and flame-shaped. 
• Hard exudates. 
• Soft exudates/cotton wool spots. 
• Pre-proliferative retinopathy : 
• Multiple blot haemorrhages. 
• Intraretinal microvascular abnormalities (IRMAs). 
• Venous beading. 
• Venous reduplication. 
• Proliferative retinopathy : 
• New vessels on the disc (NVD) or within 1 disc diameter of it. 
• New vessels elsewhere (NVE). 
• Fibrovascular proliferation & tractional retinal detachment. 
• Pre-retinal or vitreous haemorrhage. 
• Rubeosis iridis (9 neovascular glaucoma). 
• Maculopathy: 
• Exudate within 1 disc diameter (DD) of the centre of the fovea. 
• Group of exudates within the macula. 
• Any microaneurysm or haemorrhage within 1 DD of the centre 
20 
 
of the fovea only if associated with a best VA of ≤6/12 (if no stereo). 
• Retinal thickening within 1 DD of the centre of the fovea (if stereo 
available). 
Other NSC grades 
• R0—no retinopathy. 
• O—other non-diabetic lesions seen (e.g. drusen and macular 
degeneration). 
• P—evidence of previous laser therapy/retinal photocoagulation. 
• U—unclassifiable, often due to cataracts 
Diabetic renal disease 
Diabetic nephropathy is now the major cause of end-stage renal 
disease (ESRD) worldwide, representing over 50% of patients on renal 
replacement therapy in many developing  countries the majority having 
type 2 diabetes. Cardiovascular morbidity and mortality is much greater 
in diabetic patients with nephropathy, and many will die before reaching 
ESRD. 
Definition 
Diabetic nephropathy is defined by the presence of dipstick 
positive proteinuria in a person with diabetes1. This equates to an albumin 
concentration of 300mg/L (total protein 0.5g/L). Most patients will also 
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have hypertension and retinopathy, and many will have renal impairment. 
Research studies use timed urine collections, with a diagnostic level of 
>300mg/day (about 200 micrograms/min). This level of albuminuria is 
termed overt or clinical nephropathy. Excretion rates between 20 and 200 
micrograms/min are called  microalbuminuria or incipient nephropathy 
and indicate a high risk for future ESRD, although as many as 30% may 
spontaneously revert to normal . 
Chronic kidney disease (CKD) has been classified into stages, 
according to an estimated glomerular filtration rate (eGFR) derived from 
serum creatinine concentrations. Stages 1 and 2 (eGFR >90 and 60–
89mL/min/1.73m2, respectively) also require the presence of albuminuria 
or renal structural abnormality, but stages 3–5 (eGFR 30–59, 15–29, and 
<15mL/min/1.73m2, respectively) do not require. The problem is that this 
classification does not map easily to the classical definition of incipient 
and overt nephropathy. Moreover, not all CKD is due to diabetic 
glomerulosclerosis, particularly in the older person with type 2 diabetes, 
although the presence of retinopathy makes the likelihood of diabetic 
glomerulosclerosis >80%. 
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Diabetic neuropathy 
Definition 
Involvement of cranial, peripheral, and autonomic nerves may be 
found in patients with diabetes and termed diabetic neuropathy; this 
usually suggests a diffuse, predominantly sensory peripheral neuropathy. 
The  effects  on  nerve  function  can  be  both  acute  or  chronic  as  well  as  
being transient or permanent. The commonest clinical consequences of 
neuropathy are: 
• Altered sensation (both pain and i sensitivity to normal sensation). 
• Neuropathic ulcers, usually on the feet. 
• Erectile dysfunction (with autonomic neuropathy). 
• Charcot arthropathy. 
Pathology 
Diabetic neuropathy is one of the microvascular complications of 
diabetes. 
Pathologically, distal axonal loss occurs with focal demyelination 
and attempts at nerve regeneration. The vasa nervorum often shows 
basement membrane thickening, endothelial cell changes, and some 
occlusion of its lumen. This results in slowing of nerve conduction 
velocities or a complete loss of nerve function. Both metabolic and 
vascular changes have been implicated in its aetiology. 
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Classification of diabetic neuropathies 
• Sensory neuropathy: 
• Acute. 
• Chronic. 
• Autonomic neuropathy: 
• Erectile dysfunction. 
• Gastroparesis. 
• Postural hypotension. 
• Mononeuropathy: 
• Entrapment neuropathy. 
• External pressure palsies. 
• Spontaneous mononeuropathy. 
• Proximal motor neuropathy (diabetic amyotrophy) 
Macrovascular disease 
People with diabetes have a significantly greater risk of 
macrovascular complications (coronary heart disease, cerebrovascular 
disease, and peripheral vascular disease) than the non-diabetic 
population2. Around three-quarters of people with diabetes will die as a 
result of macrovascular disease, and a diagnosis of type 2 diabetes 
equates to a cardiovascular risk equivalent of ageing 10–15 years. 
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Hypertension is twice as common in the diabetic population as in 
the non-diabetic population, and standard ethnic differences in the 
prevalence of hypertension still hold true. It is known that hypertension 
worsens the severity and increases the risk of developing both 
microvascular and macrovascular disease. Using a cut-off of 
>160/90mmHg, hypertension occurs in: 
• 10–30% of patients with type 1 diabetes. 
• 20–30% of microalbuminuric type 1 patients. 
• 80–90% of macroalbuminuric type 1 patients. 
Using the UKPDS suggested target of 140/80, hypertension is even 
more common. 
Pathogenesis 
• Type 1 patients. Hypertension is strongly associated with diabetic 
nephropathy and microalbuminuria and occurs at an earlier stage than that 
seen in many other causes of renal disease. 
• Type 2 patients. Hypertension is associated with insulin resistance and 
Hyperinsulinaemia57.  Hyperinsulinaemia can directly cause hypertension 
by increased sympathetic nervous system activity, enhanced proximal 
tubule sodium reabsorption, and stimulation of vascular smooth muscle 
cell proliferation. 
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                                       MAGNESIUM   
Introduction :  
Magnesium (Mg) is the fourth most abundant cation and second 
most abundant intracellular cation52. Magnesium plays an essential role in 
a wide range of fundamental biological reactions35. Kruse and associates 
made the first systemic observations of magnesium deficiency in rats and 
dogs22.Early description of clinical depletion of magnesium in man 
published in 193423  
Distribution :  
Bone has the maximum content of magnesium in the body with 
more than 50 % segmented in it35.  Rest  is  in  the  soft  tissues;  the  total  
intracellular content of mg is 8 to 10 mmol/l33. Approximate daily intake 
averages between 250 – 300 mg/day; fecal excretion is 2.5 mg / kg / day; 
urinary excretion is 1.5 mg/ kg/day52. 
TOTAL BODY CONTENT 24GM IN ADULT MALE 
BONE Ø 50% 
EXTRACELLULAR FLUID             1% 
SERUM 1.7-2.4 MG% 
ULTRAFILTRABLE MG           75% 
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IONIZED           60% 
COMPLEXED           15% 
PROTEIN BOUND           25% 
 
Role of intestine:  
About 30-40% of ingested magnesium is absorbed, in the small 
intestine mainly in jejunum and ileum. This absorption is enhanced by 1, 
25 (OH)2 Vitamin D45,,52. Growth hormone slightly increases Mg 
absorption. Aldosterone and Calcitonin appear to reduce it. Vitamin B6 
has been reported to enhance the absorption.  
Role of kidney:  
Kidneys regulate the excretion of magnesium and thus form the 
main control of plasma levels4. Around 25% of filtered Mg is reabsorbed 
in the proximal tubule and 65% is reabsorbed in thick  ascending loop of 
Henle and 5% in distal convoluted tubule53. Para thyroid hormone, 
Vasopressin, calcitonin, glucagon increase tubular magnesium 
reabsorption, whereas acetyl choline, bradykinin, and atrial natriuretic 
peptide stimulate urinary magnesium excretion52 
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Biological role of magnesium:  
Enzymes of the intermediary metabolism and nucleic acid 
metabolism depend on magnesium for their effective action. Almost five 
enzymes of the glycolytic pathway depend on magnesium ;This comes as 
no surprise since four of the five ( hexokinase , phosphofructokinase, 
phosphoglycerate kinase , pyruvate kinase and enolase ) ;three of the four 
key enzymes in the gluconeogenesis pathway require magnesium45. Lipid 
metabolism and RNA, DNA polymerases also need magnesium; 
transketolase reaction in thiamine metabolism; transfer of CO2 to biotin 
in carboxylation reactions; glutathione has an Mg requirement for its 
synthesis24. The second messenger cyclic adenosine monophosphate 
formed by the action of the enzyme adenylate cyclase is activated by Mg.  
HYPERMAGNESEMIA 
Exclusive hypermagnesemia is very rare unless there is underlying 
renal failure. Kidneys excrete normally 250 mmol/d of magnesium daily2.  
Causes:  
1. Impaired excretion  
Renal failure  
Familial hypocalciuric hypercalcemia  
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2. Rapid mobilization from soft tissues  
Trauma, Shock, Sepsis, Cardiac arrest  
3. Excessive intake  
Cathartics, Parenteral nutrition, Urologic irrigants   
4. Others  
Adrenal insufficiency, Hypothyroidism, Hypothermia  
Signs and symptoms:  
Unless the level of magnesium raises above 4.8 mg / dl patients are 
asymptomatic ; when such a situation occurs three types of manifestations 
can occur namely neuromuscular, cardiovascular, hypocalcemic 
symptoms.  
Neuromuscular effects:  
These are the most commonly observed and most consistently 
observed effects of hypermagnesemia. Hypermagnesemia decreases the 
release of acetyl choline and suppresses the transmission across the 
neuromuscular junction producing curare like effects25,26 .With a plasma 
magnesium level of 4.8-7.2 mg/dl patients develop lethargy, drowsiness, 
muscle weakness, decreased deep tendon reflexes leading to flaccid 
quadriplegia, and respiratory depression.  
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Cardiovascular effects:  
Bradycardia and hypotension occur at plasma concentration of 4.8-
6mg/dl. At concentration of 6 to 12g/dl prolongation of PR interval, 
widening of QRS duration and increase in QT interval occur. 
At plasma concentration of 18 mg/dl complete heart block and 
cardiac arrest can occur27  
Hypocalcemic effects:  
Moderate hypermagnesemia can inhibit the secretion of 
parathyroid hormone, causing reduction in plasma level of calcium 
causing hypocalcemic symptoms28 
 Other symptoms:  
Nonspecific symptoms like nausea, vomiting and flushing can occur  
Treatment:  
Maintain hydration  
Calcium 100-200mg over 1-2 hrs intravenously given, can improve 
symptoms temporarily  
Treatment of the cause for Hypermagnesemia  
Haemodialysis is effective and required in case of renal failure 
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HYPOMAGNESEMIA  
Hypomagnesemia refers to low serum magnesium concentrations, 
clinically it is defined as serum concentration less than or equal to1.6 
mg/dl or >2 SD below the mean general population16,29. In patients 
suspected with magnesium deficiency a low serum magnesium 
concentration is sufficient to confirm the diagnosis57.  
Causes of Hypomagnesemia:  
1.  Drugs and toxins  
 Ethanol  
 Diuretics  
 Cisplatin  
 Aminoglycosides  
2.  Renal diseases  
Tubulointersitial disease  
ATN diuretic phase  
Renal transplantation  
Gitelman syndrome   
Barters syndrome  
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3.  Intestinal disorders  
Malabsorption syndromes  
Intestinal drainages, fistulas  
Protracted vomiting, diarrhea  
4.  Metabolic causes  
 Hyperaldosteronisum  
 SIADH  
 Diabetes mellitus  
 Hypercalcemia  
 Metabolic acidosis  
 Hyperthyroidism  
5.  Others  
 Pancreatitis  
 Burns  
 Excessive sweating  
 Pregnancy  
Incidence:  
 Hospitalized patients show an increased incidence of 
hypomagnesemia with studies showing incidence of 12 %30. This is 
more in intensive care settings due to the drugs being used there ; studies 
have shown incidence of around 60% 52.  
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Symptoms and signs:  
Only when serum magnesium concentration falls below1.2mg/dl 
symptoms and signs occur, till then usually patients are asymptomatic54. 
The symptoms are muscle cramps, hyperactive deep tendon reflexes, and 
dysphagia, irritability, disorientation, trousseau and chvostek signs. 
Ataxia, nystagmus and seizures occurs at the serum level of <0.8mg/dl 
.Paroxysmal atrial and ventricular dysarrhythmias may also develop.  
ECG:  
ECG shows nonspecific findings. Modest depletion of Mg (1.2 to 
1.7 mg/dl) leads to QRS complex widening with peak T waves, where as 
severe magnesium depletion (<1.2mg/dl) shows PR interval prolongation, 
progressive widening of QRS complex, flattening or inversion of T waves 
and U waves55  
Lab studies:  
Because of only small fraction of magnesium present in ECF the 
serum Mg is not a reliable indicator of total body magnesium depletion. 
Nevertheless a deficiency of magnesium is clearly present if serum 
magnesium is low56 .Serum magnesium is measured by Calmagite dye 
method, equilibrium dialysis, atomic absorption spectrometry, ion 
selective electrodes and neutron activation analysis.  
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Treatment:  
Asymptomatic mild hypomagnesemia can be treated with oral 
magnesium salts like magnesium chloride (MgCl2),magnesium oxide 
(MgO), magnesium hydroxide (Mg(OH2)) in dose of 40-60meq/day, 
whereas severe hypomagnesemia requires parenteral therapy with 
magnesium chloride (MgCl2) as a continuous infusion of 100 meq/day in 
case of normal renal function. During management serum magnesium 
should be monitored at intervals of 12-24hrs.  
HYPOMAGNESEMIA AND DIABETES MELLITUS  
Most common disorder associated with magnesium depletion is 
diabetes mellitus32,33. Hypomagnesemia occurs in 13.5 to 47.7% of non 
hospitalized type2 DM patients compared to 2.5% to 15% among their  
counterparts without diabetes34-37.There is inverse relationship between 
serum Mg levels and glycemic control16,34,38-40. Hypomagnesemia alters 
the glucose transport, and decreases the insulin secretion, affects the post 
receptor insulin signaling and interactions. Studies show correlation 
between serum Mg levels and glycemic control and also improvement of 
glycemic control with Mg supplementation9,35  
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Causes of hypomagnesemia in Type 2 Diabetes Mellitus3:  
1.  Decreased intake  
 Poor oral intake  
 Esophageal dysfunction  
 Diabetic gastro paresis  
2.  Increased GI loss  
 Diarrhea due to autonomic dysfunction  
3.  Increased renal loss  
 Glomerular hyper filtration, osmotic diuresis, volume expansion, 
metabolic acidosis, hypoalbuminemia, microalbuminuria, Overt 
proteinuria, Insulin deficiency or resistance status and diuretics.  
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HYPOMAGNESEMIA AND ADVERSE CLINICAL EVENTS IN 
TYPE 2 DM  
Non enzymatic glycosylation is the basic process underlying many 
of the long term complications of diabetes mellitus ; low magnesium 
levels also play a role in this regard5. Abou seif et al found that low serum 
magnesium is associated with defective anti oxidative processes in type 2 
DM .Paolisso and Barbagallo et al57 found that low serum magnesium 
diminishes the tyrosine kinase activity and increases the vascular 
resistance by calcium. This mechanism may account for hypertension and 
peripheral insulin resistance. The etiological role of magnesium in 
diseases like cerebrovascular disease, peripheral vascular disease and 
cardiac disease may be due to its role in inducing atherosclerosis ; It is 
observed that the serum Mg has inverse association with fasting serum 
glucose, insulin and systolic arterial blood pressure4,6. Hypomagnesemia 
has been seen in patients with diabetic retinopathy; with lower levels 
carrying an increased risk of severe diabetic retinopathy. Corsonello et al 
reported that low serum Mg is associated with diabetic nephropathy. 
Recent retrospective studies show an association between low serum Mg 
and renal function deterioration in type 2 DM16. Dee leewu et al58 
observed that polyneuropathy was related to the duration of disease and 
low serum Mg concentration and with supplementation of magnesium 
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decreasing the incidence of neuropathy .In type 2 DM development of 
feet ulcers are associated with low serum Mg levels21 
MAGNESIUM SUPPLEMENTATION IN TYPE 2 DM  
Various studies have proved that magnesium replacement can 
lessen the pathogenic factors and morbidities associated with type 2 
diabetes mellitus like platelet reactivity, cardiovascular morbidity and 
insulin resistance19.  In a case control study done by Paolisso et al57, oral 
supplementation of 250 mg twice daily decreased the insulin 
requirements especially in elderly patients. They demonstrated an 
increase in beta cell response in response to glucose and arginine. 
Magnesium supplementation has been shown to decrease systolic blood 
pressure by > 5 mm hg in diabetic patients14 . 
It also has a beneficial effect on lipid profile;  
The response to insulin is increased thereby decreasing the insulin 
requirement in patients who are supplemented with magnesium. This has 
been also proved conclusively by Poonam Agrawala et al51 . 
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METHODOLOGY 
Patients with diabetes mellitus-both type 1and type 2 admitted in 
general medical ward/attending diabetology outpatient department of 
Government Royapettah Hospital. 
Methods: 
150 patients with diabetes mellitus who were admitted in general 
medical wards/attended diabetology outpatient department were selected 
randomly for the study. Detailed history, thorough clinical examination, 
and relevant biochemical investigations were obtained from all patients. 
Inclusion criteria: 
Diabetes mellitus patients aged 18-75 years admitted in general 
medical wards/attending diabetology out patient department in 
Government Royapettah Hospital. 
Exclusion criteria: 
1. Chronic diarrhea 
2. Malabsorption 
3. Patients on diuretics. 
4. Patients with renal failure 
5. Patients receiving magnesium supplements or magnesium 
containing antacid. 
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6. Patients with alcohol abuse 
7. Patients with acute complications of diabetes mellitus. 
Investigations: 
Fasting blood sugar. 
Post prandial blood sugar was measured 2 hrs after a standard meal. 
24  hours urine albumin was estimated. 
Serum magnesium-Calmagite dye method with spectrophotometric 
testing at 530 nm. 
Blood urea, serum creatinine. 
Chest X ray, ECG, Echocardiogram. 
Direct ophthalmoscopy. 
Normal serum magnesium was defined as ievel of 1.7-2.4 mg/dl. 
Patients were divided and categorized as with normal serum 
magnesium:1.7-2.4 mg/dl; low serum magnesium:< 1.7 mg/dl ;high >2.4 
mg/dl. Patients were further categorized on the basis of duration of 
diabetes, mode of treatment, presence of hypertension, IHD, presence 
/absence of retinopathy, neuropathy, nephropathy and glycemic control 
Diabetic retinopathy was classified as proliferative retinopathy and non 
proliferative retinopathy. Diabetic nephropathy was graded using 24 hour 
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urine protein excretion as no nephropathy if < 30 mg/24 hr; 
microalbuminuria 30-299 mg/24 hr and macroalbuminuria >300 mg/24 
hr. 
Statistical method: 
          Statistical method analysis was done using chi square test and 
sample variable t test to compare the proportions. Results were 
considered significant at p value < 0.05. 
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RESULTS 
 
This study comprised 150 patients with diabetes mellitus. These 
patients were further grouped according to their age, duration of diabetes, 
mode of treatment, glycemic control, presence or absence of co 
morbidities(hypertension and ischaemic heart disease) and presence 
/absence of diabetic complications.(retinopathy, neuropathy and 
nephropathy) 
TABLE 1: AGE DISTRIBUTION 
Age group No of patients % 
Upto 30 yrs 12 8.0 
31-40 2 1.3 
41-50 43 28.7 
51-60 64 42.7 
Above 60 29 19.3 
Total 150 100 
Mean 52.16  
Sd 11.007  
 In our study maximum number of  diabetics were in the 51-60 
years age group. Youngest patient in our study was about 19 years. Mean 
age of the study population is 52.16. 
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CHART 1 
AGE DISTRIBUTION 
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TABLE 2: AGE DISTRIBUTION AND MAGNESIUM 
LEVELS: 
AGE 
GROUP 
NORMOMAGNESEMIA HYPOMAGNESEMIA TOTAL 
Number % Number % Number % 
< 30 yrs 9 9.3 3 5.7 12 8 
31-40 1 1.0 1 1.9 2 1.3 
41-50 41 42.3 2 3.8 43 28.7 
51-60 40 41.2 24 45.3 64 42.7 
>60 yrs 6  6.2 23 43.4 29 19.3 
Total 97 100 53 100 150 100 
 
The maximum number of individuals with hypomagnesemia were in the 
age group of 51-60 years. Almost 80% of individuals above the age group 
of 60 were hypomanesemic. 
AGE NORMOMAGNESEMIA HYPOMAGNESEMIA 
<30 9.3% 5.7% 
31-40 1.0% 1.9% 
41-50 42.3% 3.8% 
51-60 41.2% 45.3% 
>60 6.2% 43.4% 
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CHART 2 
AGE DISTRIBUTION WITH  HYPOMAGNESEMIA                                    
AND NORMOMAGNESEMIA 
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CHART 3 
PREVALANCE OF HYPOMAGNESEMIA 
 
 
Out of 150 patients in the study, 65% of individuals had normal 
magnesium levels and remaining 35% of individuals had 
hypomagnesemia. 
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TABLE 3: GENDER DISTRIBUTION 
Sex Number % Valid % 
Male 67 44.7 44.7 
Female 83 55.3 55.3 
Total 150 100 100 
 
In our study, females were more than males. Females constituted 55.3% 
while males were 44.7% 
CHART 4 
GENDER DISTRIBUTION 
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TABLE 4: TYPES & DISTRIBUTION 
Type Number % Valid % 
Type 1 14 9 9 
Type2 136 91 91 
Total 150 100 100 
 
In our study,14 individuals were of type1DM while 136 individuals 
belong to type 2 DM. They correspond to 9% and 91% of population 
studied respectively. 
CHART 5 
DM DISTRIBUTION 
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TABLE 5: MODE OF THERAPY 
Management Number % Valid% 
INS 58 38.7 38.7 
OHA 92 61.3 61.3 
TOTAL 150 100 100 
 
In our study,61.3% of study population were taking oral hypoglycaemic 
agents while 38.7% of individuals were on insulin. 
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TABLE 6: MODE OF THERAPY  WITH MAGNESIUM  
LEVELS 
MANAGEMENT NORMOMAGNESEMIA HYPOMAGNESEMIA 
TOTAL 
NUMBER % NUMBER % 
OHA 79 81.4 13 24.5 92 
INSULIN 18 18.6 40 75.5 58 
TOTAL 97 100 53 100 150 
CHI SQUARE 46.81 
Df 1 
SIGNIFICANT 0.0005 
 
Out of 92 individuals taking OHA, 79 individuals have 
normomagnesemia and 13 (14.13%) individuals have hypomagnesemia. 
In insulin group,40 of 58 have  hypomagnesemia ; this accounts for 
68.96%.There is a significant correlation between insulin usage and 
hypomagnesemia. 
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CHART 6 
MODE  OF  THERAPY  WITH   MAGNESIUM  LEVELS  
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CHART 7 
RANGE OF FBS 
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TABLE 7:FBS AND SERUM MAGNESIUM LEVELS 
FBS 
NORMOMAGNESEMIA HYPOMAGNESEMIA 
TOTAL 
NUMBER % NUMBER % 
<90 3 3.1 0 0 3 
91-100 17 17.5 0 0 17 
101-110 24 24.7 5 9.4 29 
111-120 34 35.1 8 15.1 42 
121-130 14 14.4 17 32.1 31 
>130 5 5.2 23 43.4 28 
TOTAL 97 100 53 100 150 
CHI SQUARE                      51.97 
  Df    5 
SIGNIFICANT                     0.0005 
  
In our study, 23 out of 28 individuals with FBS above 130 mg% 
had hypomagnesemia. In individuals with fasting blood glucose value 
between 121-130 mg%,17 out of 31 individuals have hypomagnesemia. 
Similarly 8 patients with FBS in 111-120 mg% had hypomagnesemia.The 
incidence of hypomagnesemia is less with more tight  glycaemic control 
as evidenced by fasting blood sugar. 
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                                              CHART 8 
                   FBS AND SERUM MAGNESIUM LEVELS 
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CHART 9 
PREVALANCE OF HYPOMAGNESEMIA WITH  FBS 
RANGE 
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CHART 10 
DIABETICS AND THEIR DURATION 
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TABLE 8: DURATION OF DM WITH MAGNESIUM 
LEVELS 
DURATION 
NORMOMAGNESEMIA HYPOMAGNESEMIA TOTAL 
NUMBER % NUMBER % NUMBER % 
< 5 YRS 43 44.3 3 5.7 46 30.7 
6-10 YRS 43 44.3 19 35.8 62 41.3 
11-15 YRS 8 8.2 20 37.7 28 18.7 
16-20 YRS 3 3.1 9 17 12 8 
>20 YRS - - 2 3.8 2 1.3 
TOTAL 97 100 53 100 150 100 
 
In our study,2 patients were having diabetes for more than 20 years 
and both were hypomagnesemic. Maximum number of patients with 
hypomagnesemia were in the group of individuals  having diabetes for 
11-15 years. The incidence of  hypomagnesemia increased as the duration 
of diabetes increases. The df is 4 and by Pearson Chi Square remains 
significant with p<0.0005. 
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 CHART 11 
PREVALANCE OF HYPOMAGNESEMIA WITH DM 
DURATION 
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TABLE 9: DM AND RETINOPATHY 
RETINOPATHY NUMBER % 
NIL 95 63.3 
NPDR 41 27.3 
PDR 14 9.3 
TOTAL 150 100 
 
41 patients have non proliferative diabetic retinopathy and 14 
patients have proliferative diabetic retinopathy; they correspond to 27.3% 
and 9.3% respectively. 
CHART 12 
DM AND RETINOPATHY 
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TABLE 10: RETINOPATHY AND SERUM MAGNESIUM  
LEVELS 
RETINOPATHY 
NORMOMAGNESEMIA HYPOMAGNESEMIA 
TOTAL 
NUMBER % NUMBER % 
NIL 87 89.7 8 15.1 95 
NPDR 9 9.3 32 60.4 41 
PDR 1 1 13 24.5 14 
TOTAL 97 100 53 100 150 
CHI SQUARE 83.12 
Df 2 
SIGNIFICANT 0.0005 
 
In our study, out of 41 patients with non proliferative diabetic 
retinopathy 32 patients have hypomagnesemia. Similarly out of 14 
patients with proliferative diabetic retinopathy,13 patients have 
hypomagnesemia. 
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CHART 13 
RETINOPATHY AND SERUM MAGNESIUM  LEVELS 
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TABLE 11: DM AND NEUROPATHY 
NEUROPATHY NUMBER % 
YES 14 9.3 
NO  136 90.7 
TOTAL 150 100 
 
14 out of 150 patients had developed neuropathy in our study; this 
corresponds to 9.3% of the study population. 
CHART 14 
DM AND NEUROPATHY 
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TABLE 12: NEUROPATHY AND SERUM MAGNESIUM  
LEVELS 
NEUROPATHY 
NORMOMAGNESEMIA HYPOMAGNESEMIA 
TOTAL 
NUMBER % NUMBER % 
YES 0 0 14 9.3 14 
NO 97 71.3 39 28.7 136 
TOTAL 97 100 53 100 150 
CHI SQUARE 28.26 
Df 1 
SIGNIFICANT 0.0005 
 
All patients with neuropathy have hypomagnesemia in our study. 
This shows that hypomagnesemia is significantly associated with diabetic 
microvascular complication. 
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CHART 15 
NEUROPATHY AND  SERUM  MAGNESIUM   LEVELS 
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TABLE 13: DM AND NEPHROPATHY 
NEPHROPATHY NUMBER % 
MACROALBUMINURIA 18 12 
MICROALBUMINURIA 24 16 
NO PROTEINURIA 108 72 
TOTAL 150 100 
 
In our study,42 patients have proteinuria which corresponds to 28% of 
study population. 
CHART 16 
DM AND NEPHROPATHY 
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TABLE 14: NEPHROPATHY AND SERUM  MAGNESIUM  
LEVELS 
NEPHROPATHY 
NORMOMAGNESEMIA HYPOMAGNESEMIA 
TOTAL 
NUMBER % NUMBER % 
MACROALBUMINUIA 0 0 18 34 18 
MICROALBUMINURIA 7 7.2 17 32 24 
NO 90 92.8 18 34 108 
TOTAL` 97 100 53 100 150 
CHI SQUARE 62.65 
Df 2 
SIGNIFICANT 0.0005 
 
In our study,17 out of 24 patients with microalbuminuria have 
hypomagnesemia. Similarly ,all the 18 patients with macroalbuminuria 
have hypomagnesemia and remain statistically significant with p  value  
0.0005 
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                                                 CHART 17 
NEPHROPATHY AND  SERUM   MAGNESIUM  LEVELS 
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TABLE 15: DM AND IHD 
IHD NUMBER % 
PRESENT 34 22.7 
ABSENT 116 77.3 
TOTAL 150 100 
 
34 patients out of 150 had co existing ischaemic heart disease. This 
corresponds to 22.7% of study population. 
CHART18 
DM AND IHD 
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TABLE 16: IHD AND SERUM   MAGNESIUM LEVELS 
IHD 
NORMOMAGNESEMIA HYPOMAGNESEMIA 
TOTAL 
NUMBER % NUMBER % 
PRESENT 4 4.1 30 56.6 34 
ABSENT 93 95.9 23 43.4 116 
TOTAL 97 100 53 100 150 
CHI SQUARE 53.85 
Df 1 
SIGNIFICANT 0.0005 
 
30 patients out of 34 patients with ischaemic heart disease have 
hypomagnesemia and hence hypomagnesemia corresponds to 
macrovascular disease and they are statistically associated significantly 
with p <0.0005 by Fishers exact test. 
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CHART 19 
IHD   AND  SERUM  MAGNESIUM  LEVELS 
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TABLE 17: DM AND HYPERTENSION 
HYPERTENSION NUMBER % 
PRESENT 54 36 
ABSENT 96 64 
TOTAL 150 100 
 
54 patients out of 150 patients with diabetes have hypertension co 
existingly; this accounts for 36% of study population. 
CHART 20 
DM AND HYPERTENSION 
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TABLE 18: HT AND SERUM MAGNESIUM LEVELS 
 
HYPERTENSION 
NORMOMAGNESEMIA HYPOMAGNESEMIA 
TOTAL 
NUMBER % NUMBER % 
PRESENT 17 17.5 37 69.8 54 
ABSENT 80 82.5 16 30.2 96 
TOTAL 97 100 53 100 100 
CHI SQUARE 40.667 
Df 1 
SIGNIFICANT  0.0005 
 
37 patients out of 54 patients with hypertension have coexisting 
hypomagnesemia; this corresponds to 68.51% of hypertensives in our 
study and they are significantly associated statistically. 
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CHART 21 
HTN  AND  SERUM  MAGNESIUM  LEVELS 
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TABLE 19: DM WITH RETINO & NEUROPATHY 
RETINOPATHY & 
NEUROPATHY 
NUMBER % 
ABSENT 137 91.3 
PRESENT 13 8.7 
TOTAL 150 100 
 
13 patients had both retinopathy and neuropathy in the study population. 
This attributes to about 8.7% of the study group. 
TABLE 20: PREVALANCE OF HYPOMAGNESEMIA 
HYPOMAGNESEMIA NUMBER % 
NIL 49 92.5 
RETINOPATHY & 
NEUROPATHY 
4 7.5 
TOTAL 53 100 
 
Hypomagnesemia was seen in 4 patients with  both retinopathy and 
neuropathy out of the 13 individuals totally. 
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TABLE 21: DM WITH RETINO & NEPHROPATHY 
RETINOPATHY & 
NEPHROPATHY 
NUMBER % 
ABSENT 114 76 
PRESENT 36 24 
TOTAL 150 100 
 
Regarding presence of retinopathy and nephropathy there was a 
significant proportion of diabeticic individuals with both these 
complications-24 in number which corresponds to 24 % of the study 
population. 
TABLE 22:PREVALANCE OF HYPOMAGNESEMIA 
HYPOMAGNESEMIA NUMBER % 
NIL 42 79.2 
RETINOPATHY & 
NEPHROPATHY 
11 20.8 
TOTAL 53 100 
 
11 patients with both retinopathy and neuropathy had 
hypomagnesemia  among the 36 patients who had both these 
complications in the entire study group. 
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TABLE 23: DM WITH NEURO & NEPHROPATHY 
NEUROPATHY & 
NEPHROPATHY 
NUMBER % 
ABSENT 137 91.3 
PRESENT 13 8.7 
TOTAL 150 100 
 
Neuropathy was the least of all three microvascular complications and co 
existence of neuropathy with nephropathy attributed to 8.7 % of the 
population and were 13 individuals in number. 
TABLE 24:PREVALANCE OF HYPOMAGNESEMIA 
HYPOMAGNESEMIA NUMBER % 
NIL 49 92.5 
NEUROPATHY & 
NEPHROPATHY 
4 7.5 
TOTAL 53 100 
Out of the 13 individuals who had both neuropathy and 
nephropathy, 4 patients  have hypomagnesemia in investigational 
population. 
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                                            CHART 22 
                 PREVALANCE OF HYPOMAGNESEMIA 
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DISCUSSION 
Hypomagnesemia is significantly associated with diabetes mellitus 
and has been well demonstrated by several studies; hypomagnesemia is 
well associated with complications of diabetes both microvascular and 
macrovascular  and the fact is proven beyond doubt by many studies. 
Hence I found it worthy to pursue this study in our setting. 
DIABETES AND HYPOMAGNESEMIA: 
          In our study , 150 individuals with diabetes were randomly selected 
and evaluated; among  65% of individuals had normal serum magnesium 
levels while 35% of individuals had reduced serum magnesium levels. 
The prevalence of hypomagnessemia as reported by Pham PC, Pham PM, 
Miller JM et al ranges from 13.5% to 47.7% in diabetics which very well 
corresponds to our study. 
          Reduced serum magnesium in diabetic individuals may  be the 
result of increased urinary loss, low dietary intake, reduced 
gastrointestinal absorption .Christian MS et al found increased urinary 
excretion of magnesium in their study. Reduced oral intake may not be a 
major factor in precipitating hypomagnesemia. Defective tubular 
reabsoption has also been postulated for development of 
hypomagnesemia. 
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AGE , SEX IN DIABETICS AND HYPOMAGNESEMIA: 
         In our study maximum number of diabetics were in the age group of 
51-60 years. Hypomagnesemia was significantly found in the  same age 
group with diabetes and people more than 60 years were almost found to 
have  hypomagnesemia.  Study  by  Al  Osali  ME,  Al  Qassabi  SS  et  al  
demonstrated  correlation between age ,male sex in diabetics with low 
magnesium levels. But in our study females are far more in number than 
males with diabetes and hypomagnesemia. 
DURATION, MODE OF TREATMENT & HYPOMAGNESEMIA: 
        In our study,19 out of 62 patients who have diabetes for 6- 10 years 
have hypomagnesemia; while 28 patients had diabetes for 11-15 years of 
which 20 have hypomagnesemia; similarly 12 patients had diabetes for  
16-20 years of which 9 have hypomagnesemia and 100% of individuals 
with diabetes > 20 years had hypomagnesemia; p value for duration of 
diabetes and hypomagnesemia was significant namely 0.0005. 
       58 patients were on insulin and 92 patients were on OHA  in our 
study; 40 out of 58 individuals had hypomagnesemia (68.96%) and p 
value was statistically significant. Only 13 out of 92 patients on OHA had 
hypomagnesemia. Our results correspond to study results of  Alzaida et 
al. 
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FASTING BLOOD SUGAR & HYPOMAGNESEMIA : 
        Schieinger et al found the relationship between poor glycaemic 
control and low serum magnesium levels. In our study,28 patients have 
FBS above 130 mg%  and 24 patients in this group have 
hypomagnesemia. With statistical analysis those with poor glycaemic 
control had associated hypomagnesemia which is statistically significant 
as evident by p value < 0.001. 
DIABETIC RETINOPATHY AND HYPOMAGNESEMIA: 
           In our study,55 patients had retinopathy ;among them 45 
patients(81.8%) had co existing hypomagnesemia. Moreover 14 patients 
had proliferative diabetic retinopathy ;out of which 13 patients had 
hypomagnesemia.With statistical analysis this is found to be significant 
and the p value is <0.0005.Similar studies showing association of 
hypomagnesemia with retinopathy are of Gujral AS et al and Cariello A 
et al. 
DIABETIC NEUROPATHY & HYPOMAGNESEMIA: 
      In our study ,14 patients have neuropathy and all the 14 have 
hypomagnesemia which becomes statistically significant with a p value 
of <0.0005.Rodriguez moran et al showed association of 
hypomagnesemia with diabetic neuropathy and ulcer in foot. 
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DIABETIC NEPHROPATHY & HYPOMAGNESEMIA: 
       42 patients had nephropathy out of 150 individuals;this 
corresponds to 28% of study population. In patients with nephropathy ,35 
patients have hypomagnesemia(83.33%) and this is statistically 
significant  with a p value of  <0.0005.Study done by Pham PC et  al  and 
Corsenallo support the above said association. 
CARDIOVASCULAR MORBIDITY & HYPOMAGNESEMIA : 
       In our study,4 patients in normomagnesemia group (4.1%) and 30 
patients in hypomagnesemia group have ischaemic heart disease (56.6%) 
and this remains statistically significant with a p value of ,0.005 with 
Fischers exact test. 
     17 patients in normomagnesemia group had hypertension(17.5%)  
and 37 patients in hypomagnesemia group had hypertension(69.8%).The 
above  results  are  supported  by  studies  by  Guerrero  et  al   and  Sharma   
et al. 
     Retinopathy, neuropathy and nephropathy were the principal 
complications whose association with low serum magnesium levels were 
evaluated for and with statistical analysis ,a significant correlation has 
been found with a p value of <0.005. 
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SUMMARY AND CONCLUSION 
Our study included 150 diabetic individuals who were admitted in 
general medicine wards/attended diabetology  out patient department of  
Government Royapettah Hospital. Summarizing the results of our study 
1. 53 diabetic individuals had hypomagnesemia(35.3%) 
2. Prevalance of hypomagnesemia increased with age. 
3. Prevalance of hypomagnesemia increased with prolonged duration 
of diabetes mellitus. 
4. Hypomagnesemia was significantly associated with poor 
glycaemic control as evidenced by higher fasting blood glucose. 
5. Patients with diabetic retinopathy, neuropathy and nephropathy had 
significant association with hypomagnesemia as evidenced by p 
value. 
6. The incidence of hypomagnesemia was less proportionately  in 
type 1 DM patients when compared with type 2 DM. 
7. Hypomagnesemia was significantly correlated with ischaemic heart 
disease and hypertension. 
8. The proportion of  diabetics with hypomagnesemia was more with 
insulin therapy than with oral hypoglycaemic drug therapy. 
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CONCLUSION: 
1. There is a significant prevalence of low serum magnesium level in 
individuals with diabetes mellitus. 
2.  Hypomagnesemia is significantly associated with both 
microvascular and macrovascular complications of both type1 and 
type 2 diabetes mellitus patients.                                                           
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PROFORMA 
 
PATIENT DETAILS :  
Name :  
Inpatient No :  
Age :  
Sex :  
Occupation :  
DIABETIC HISTORY :  
Age of onset :  
Total duration :  
Mode of treatment :  
Oral hypoglycemic agents :  
Insulin :  
SYMPTOMS RELATED TO COMPLICATIONS :  
a) Symptoms of neuropathy  
Postural dizziness  
Weakness  
Numbness / Paraesthesia  
Bladder incontinence  
Impotence  
b) Symptoms of nephropathy  
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Oliguria  
Oedema 
c)Symptoms of retinopathy 
  Dimness of vision 
  Blindness 
PAST HISTORY 
 Hypertension, Ischaemic heart disease, Chronic Kidney disease. 
PERSONAL HISTORY: 
Smoking, alcohol abuse 
FAMILY HISTORY : 
Diabetes Mellitus 
Hypertension 
Ischaemic heart disease 
 
GENERAL EXAMINATION :  
Pulse rate :  
Blood pressure :  
Consciousness :  
Orientation :  
Icteric/ Anemic :  
Cyanosis / Clubbing : 
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BPPE/Puffiness of face : 
CARDIOVASCULAR SYSTEM EXAMINATION: 
RESPIRATORY SYSTEM EXAMINATION: 
ABDOMINAL EXAMINATION: 
CENTRAL NERVOUS SYSTEM EXAMINATION: 
       Higher mental function examination: 
       Cranial nerve examination: 
       Fundus examination: 
MOTOR SYSTEM EXAMINATION: 
     Wasting 
      Tone 
Reflexes :  
SENSORY SYSTEM EXAMINATION :  
INVESTIGATIONS :  
URINE: 
Albumin  
Sugar 
Deposit 
24 hr urine protein 
RENAL FUNCTION TEST: 
   Urea 
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  Creatinine 
FASTING BLOOD SUGAR 
POSTPRANDIAL BLOOD SUGAR 
SERUM ELECTROLYTES 
         Sodium 
         Potassium 
         Bicarbonate 
         Chloride 
       Fasting serum magnesium 
ELECTROCARDIOGRAM 
ECHOCARDIOGRAM 
ULTRASOUND ABDOMEN 
FASTING LIPID PROFILE 
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MASTER CHART 
NAME AGE SEX HOSP NO AOD DUR MGNT FBS PPBS Mg IHD HT RETI NEUR NEPH 
PANDIAN 52 M 62272 48 4 OHA 117 169 1.8 - - NIL - - 
BALA 47 M 45 2 OHA 89 152 1.9 NIL 
SEKAR 48 M 40 8 OHA 129 189 1.2 NPDR 
SELVI 49 F 62233 42 7 OHA 114 178 2.1 NPDR 
NIRANJAN 56 M 46 10 INS 140 190 1.1 NPDR MIC 
SUBRAMANIAN 60 M 67349 48 12 INS 120 201 1.1 + + NPDR NEURO MAC 
LAKSHMI 55 F 67295 51 4 OHA 87 143 2.2 NIL 
JAVED 58 M 55 3 INS 121 194 1 + + NPDR 
VIJAYA 49 F 43 6 OHA 115 156 1.8 NIL 
MAHESH 20 M 11 8 INS 106 192 2 NIL 
ABDUL 46 M 63259 40 6 OHA 101 167 2.3 + NIL 
HITHAYA FOUSAL 52 F 45 7 INS 136 234 1.4 + NPDR MIC 
SUNDARESAN 55 M 47 8 INS 121 181 2.2 + + NPDR 
MEENAMMA 59 F 55 4 OHA 106 184 2.3 NIL 
KUMARESAN 47 M 67202 43 4 OHA 116 178 2.1 NIL 
KATHIRVELAN 54 M 49 5 OHA 123 204 2 NIL 
MANOHAR 62 M 67292 45 17 INS 129 189 1.3 + NPDR NEURO MAC 
VELU 48 M 73171 40 8 INS 115 156 1.8 NIL 
SIVAKAMI 50 F 65589 47 3 OHA 98 146 2.1 NIL 
SUMATHY 46 F 64198 43 3 OHA 102 212 2.3 NIL 
NATARAJAN 55 M 66812 49 6 INS 136 242 1.4 + + NPDR MIC 
NALLATHAMBI 59 M 74327 52 7 OHA 115 178 1.8 NIL 
ARJUN 24 M 64876 10 14 INS 110 198 2.1 NIL MIC 
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ARIVAZHAGI 56 F 62353 50 6 OHA 111 158 2.4 NIL 
SIVAKUMAR 45 M 68246 42 3 OHA 98 156 2.3 NIL 
ABU BUCKER 56 M 67304 46 10 INS 142 223 1.2 + NPDR MIC 
CHANDRAN  61 M 74212 50 11 INS 141 190 1.2 + NIL NEURO 
MOHAMMED IQBAL 62 M 69087 52 10 INS 101 170 2.1 + NPDR 
MALARVANNAN 53 M 62219 49 4 OHA 120 178 1.1 NIL 
ELUMALAI 47 M 65078 43 4 OHA 109 177 2.1 NIL 
MUBARAK ALI 53 M 66782 46 7 OHA 112 192 1.9 + NIL 
MURUGESAN 60 M 62356 52 8 INS 122 198 1.6 + + NPDR MIC 
SIVATHAMBI 43 M 64513 39 4 OHA 100 176 2.2 NIL 
ANBUMANI 47 M 67202 44 3 OHA 116 189 2.1 NIL 
LALITHA 53 F 66812 47 6 OHA 95 178 2.4 NIL 
MALARVIZHI 32 F 62336 14 18 INS 136 201 1.8 NPDR MIC 
TAJ NISHA 62 F 72243 51 11 INS 132 223 1.1 + + PDR 
TAMILSELVI 58 F 64497 45 13 INS 145 221 1.2 + NPDR NEURO MAC 
MADHAVAN 48 M 69982 45 3 OHA 124 179 1.9 + NIL 
BALAJI 20 M 67439 8 12 INS 112 183 2.2 NIL 
NARAYANAN 70 M 72986 52 18 INS 145 241 1 + + PDR NEURO MAC 
MUTHU 66 M 67296 49 17 INS 135 245 1.1 + + PDR 
SELVAM 54 M 70005 48 6 OHA 129 211 1.1 NPDR 
JEGAN 48 M 62223 44 4 OHA 107 167 2.3 NIL 
SAKTHI 44 F 64963 42 2 OHA 92 146 2.4 NIL 
SARALA 57 F 62338 46 11 INS 121 189 2.4 NIL 
DEVIAMMAL 60 F 72475 52 8 INS 125 216 1.1 + NPDR 
JAVED 64 M 64869 53 11 OHA 118 192 1.3 + + NPDR NEURO MIC 
ANANDHAN 57 M 73178 51 6 OHA 105 218 1.9 NIL 
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ZAHEERA BEE 65 F 68576 45 20 INS 136 243 1.3 + + PDR NEURO MAC 
PADMAVATHY 63 F 76534 55 8 OHA 118 187 2.4 NIL 
MANIVANNAN 56 M 72700 52 4 OHA 120 199 2 NIL 
SUSEELA 48 F 71235 42 6 OHA 118 189 1.8 NIL 
ANGAMMAL 67 F 65704 55 12 INS 137 231 1.2 + + PDR NEURO MAC 
AMARAVATHY 58 F 72571 50 8 OHA 108 167 1.1 + NIL 
RAJA 44 M 64958 41 3 OHA 114 184 2 NIL 
ALEM BEE 61 F 67568 50 11 INS 128 232 1.2 + + NPDR NEURO MAC 
ANDALAMMAL 59 F 69098 52 7 OHA 111 167 1.8 + NIL 
SEETHARAMAN 45 M 65568 44 1 OHA 123 186 2.2 NIL 
ARUL 46 M 69723 40 6 OHA 108 198 1.9 NIL 
SAHAYAM 54 M 69723 47 7 OHA 119 178 1.9 + NIL 
CHRISTOPHER 60 M 66812 51 9 INS 145 241 2.1 + NIL 
KRISHNAN 48 M 66027 45 3 OHA 120 157 1.7 NIL 
KALIDASAN 56 M 67304 48 8 OHA 124 187 2.2 NIL 
JAWAHAR 60 M 69797 52 8 OHA 110 198 1.8 + NPDR MIC 
KANNADASAN 63 M 73216 50 13 INS 132 245 1.2 + + PDR NEURO MAC 
BHARATHY 52 M 66754 49 3 OHA 120 186 1.8 NIL 
NEELAKANDAN 48 M 69652 44 4 OHA 121 197 1.2 NIL 
KALAIARASI 51 F 73208 45 6 OHA 116 178 1.9 NIL 
NEELAVATHY 64 F 71234 50 14 INS 136 226 1.1 + + NPDR NEURO MAC 
SUGUMARI 49 F 69807 43 6 OHA 97 187 2.1 + NIL 
ANU 22 F 70547 11 11 INS 128 212 1.9 NIL MIC 
PALANI 58 M 71764 50 8 OHA 98 152 1.8 NIL 
RADHA 63 F 72674 55 8 OHA 118 197 1.4 + NPDR MIC 
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AMBIGAI 55 F 65906 50 5 OHA 126 206 2.1 NIL 
KALAISELVI 56 F 69795 47 9 INS 130 245 1.2 NIL 
JEYAKUMAR 62 M 66842 53 9 OHA 104 216 1.1 + + NPDR MIC 
JOTHY 50 F 72456 45 5 OHA 109 185 2.3 NIL 
PONNI 54 F 64328 48 6 OHA 123 185 1.9 NIL 
AKILA 48 F 68743 46 2 OHA 99 163 2.4 NIL 
SIVARANJANI 61 F 69528 55 6 INS 132 226 1.3 + + NPDR MIC 
PERUMAL 65 M 70348 52 13 INS 121 243 1.1 + + PDR NEURO MAC 
HARI  29 M 70007 10 19 INS 123 214 1.7 NIL MIC 
PRASATH 52 M 65428 47 5 OHA 101 178 2.1 NIL 
SUBHA 20 F 64297 6 14 INS 108 197 1.6 NIL 
SURYA 26 M 71563 9 17 INS 114 218 1.5 NPDR MIC 
VIJAYALAXMI 51 F 74934 43 8 OHA 129 212 1.4 + + NPDR MIC 
GNANAM 50 M 74930 44 6 OHA 88 156 2.2 NIL 
SAMUNDEESWARI 51 F 72564 46 5 OHA 112 187 2.4 NIL 
ARUMUGAM 52 M 76953 44 8 OHA 108 198 1.8 + NIL 
SANGEETHA 19 F 74246 13 6 INS 118 188 1.9 NIL 
KARPAGAM 60 F 69847 50 10 INS 120 188 1 + NPDR MIC 
RAJI 26 F 68564 16 10 INS 107 231 1.7 NIL 
SHANTHI 62 F 65234 51 11 INS 126 185 1.1 + NPDR MAC 
PARAMASIVAN 68 M 70934 45 23 INS 139 222 1.2 + NPDR MAC 
ALAGAR 67 M 71784 52 15 INS 98 145 1.7 + + PDR 
SELVARAJ 60 M 72468 49 11 INS 145 231 1.1 + + PDR 
GANDHIRAM 59 M 76952 53 6 OHA 134 189 2.3 NIL 
PURUSOTHAMMAN 57 M 69847 50 7 OHA 125 209 2.2 NIL 
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POOVIZHI 50 F 74367 45 5 OHA 111 183 1.9 NIL 
SARASWATHY 52 F 63456 48 4 OHA 99 155 1.9 NIL 
SUGUMARAN 49 M 68975 45 4 OHA 100 161 1.8 NIL 
VIJAYAKUMAR 48 M 76785 45 3 OHA 101 160 2 NIL 
MAHESHWARAN 50 M 73218 46 4 OHA 102 202 2.2 NIL 
DHAYALAN 49 M 72895 44 5 OHA 118 179 1.8 NIL 
UMA 54 F 74342 48 6 OHA 98 156 2.1 NIL 
MAHESHWARI 68 F 68889 52 16 INS 120 178 1.2 + PDR MAC 
SHANMUGASUNDARAM 75 M 69870 50 25 INS 141 214 1 + + PDR MAC 
FATHIMA 57 F 76074 44 13 INS 132 243 1.3 + NPDR MIC 
ZUKHARA 59 F 76780 46 13 INS 101 178 1.5 + NPDR MIC 
FAMITHA BEEVI 62 F 73278 48 14 INS 146 228 1.1 + + PDR MAC 
KAMALAM 64 F 74893 46 18 INS 111 177 1.9 + NPDR 
SANKARAN 53 M 72565 50 3 OHA 101 189 2.1 NIL 
AMEENA 49 F 70086 40 9 OHA 107 190 1.9 NIL 
SHANMUGADEVI 38 F 69327 18 20 INS 126 197 1.4 NPDR MAC 
RAMYA 22 F 72974 14 8 INS 96 175 2.2 NIL 
SENTHILKUMAR 48 M 64893 42 6 OHA 97 167 2.3 NIL 
SHAKIRA BEEVI 60 F 74836 53 7 OHA 101 165 1.5 + + NIL MIC 
THANGAM 55 F 67364 48 7 OHA 115 178 2.1 + NIL 
MEENAKSHI 56 F 68427 50 6 OHA 120 178 2.2 NIL 
SUNDARAM 68 M 69823 53 15 INS 128 208 1.1 + + PDR NEURO MAC 
FAIZAL 51 F 66476 45 6 OHA 116 189 2 NIL 
DURGADEVI 48 F 72404 41 7 OHA 121 190 2.1 NIL 
PREMA 59 F 69986 48 11 INS 135 234 1 + NPDR 
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RAHEEM 51 M 68579 45 6 OHA 130 195 1.3 + NPDR MIC 
MENAKA 46 F 70475 43 3 OHA 112 178 1.9 NIL 
JEEVAGEETHA 56 F 71234 51 5 OHA 111 189 2.3 NIL 
GANESHKUMAR 60 M 72346 48 12 INS 142 199 1.2 + + PDR NEURO MAC 
HUSSAIN 65 M 74653 50 15 INS 128 178 1.2 + + NPDR 
ISAIVANI 46 F 75525 42 4 OHA 99 182 2.1 NIL 
KARTHIK 55 M 76414 44 11 OHA 101 176 1.9 + NPDR 
RAMAMOORTHY 62 M 75372 55 7 OHA 135 210 2.2 + + NPDR 
VENNILA 46 F 70868 41 5 OHA 98 139 2.1 NIL 
YOHALAXMI 42 F 69089 39 3 OHA 110 205 1.8 NIL 
PHILIP 59 M 76398 51 8 OHA 118 167 1.2 + NPDR 
BHASKARAN 48 M 75432 41 7 OHA 132 199 2 NIL 
LOKESHKUMAR 49 M 72498 45 4 OHA 101 185 1.9 NIL 
CHANDRAKALA 47 F 73456 42 5 OHA 93 167 2.3 NIL 
GOMATHY 55 F 74564 45 10 OHA 145 222 1.5 NPDR 
SIVAKAMI 60 F 76414 52 8 OHA 112 178 2.3 NIL 
SOLOMON 65 M 75478 48 17 INS 139 219 1.3 + + NPDR 
MURUGANANDHAM 54 M 73264 48 6 OHA 101 169 2.1 NIL 
BABU 55 M 76214 48 7 OHA 113 193 2 + NPDR MIC 
RAMESHKUMAR 52 M 74562 50 2 OHA 127 198 1.8 NIL 
BALAKUMARAN 65 M 75217 51 14 INS 130 205 1.9 + NIL MIC 
VINOTHAN 30 M 73208 13 17 INS 122 211 1.6 NIL MIC 
ROOPA 22 F 71973 10 12 INS 114 184 2.1 NIL 
SIVASANKARI 45 F 75324 41 4 OHA 114 179 1.8 NIL 
HARIHARAN 44 M 73452 40 4 OHA 102 175 2.5 NIL 
RAJKUMAR 54 M 75796 51 3 OHA 119 185 2.1 NIL 
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